Skip to main content
Top
Published in: Journal of Nuclear Cardiology 4/2017

01-08-2017 | Original Article

The high matrix acquisition technique for imaging of atherosclerotic plaque inflammation in fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography with time-of-flight: Phantom study

Authors: Masaya Suda, PhD, Tomonari Kiriyama, MD, Keiichi Ishihara, MD, Masahisa Onoguchi, PhD, Yasuhiro Kobayashi, MD, Minoru Sakurai, BS, Takayuki Shibutani, MHSc, Shin-ichiro Kumita, MD

Published in: Journal of Nuclear Cardiology | Issue 4/2017

Login to get access

Abstract

Background

Motion artifact and partial volume effect caused underestimation of coronary plaque inflammation. This study evaluated the high matrix acquisition technique using time-of-flight (TOF) positron emission tomography/computed tomography for imaging of atherosclerotic plaque inflammation with fluorine-18 fluorodeoxyglucose in small and moving phantoms.

Methods and Results

All images were reconstructed using a conventional algorithm without TOF (4 × 4 × 4 mm3 voxel size) and a high matrix algorithm with TOF (2 × 2 × 2 mm3 voxel size). Microsphere phantoms of 10, 7.9, 6.2, 5.0, and 4.0 mm diameters were acquired in 3-dimensional list-mode for 30 minutes. A heart phantom mimicking cardiac motion consisted of a hot spot simulating a plaque (φ 4 mm, φ 2 mm) on the outside of the left ventricle. In the microsphere and heart phantom study, visual discrimination, maximum activity, and target-to-background ratio using the high matrix algorithm with TOF were better than those using the conventional algorithm without TOF.

Conclusion

The high matrix algorithm with TOF improves detection of small targets in phantoms.
Appendix
Available only for authorised users
Literature
1.
go back to reference Fruchart JC, Nierman MC, Stroes ES, Kastelein JJ, Duriez P. New risk factors for atherosclerosis and patient risk assessment. Circulation 2004;109:15–9.CrossRef Fruchart JC, Nierman MC, Stroes ES, Kastelein JJ, Duriez P. New risk factors for atherosclerosis and patient risk assessment. Circulation 2004;109:15–9.CrossRef
2.
go back to reference Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002;105:1135–43.CrossRef Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002;105:1135–43.CrossRef
3.
go back to reference Quillard T, Libby P. Molecular imaging of atherosclerosis for improving diagnostic and therapeutic development. Circ Res 2012;111:231–44.CrossRef Quillard T, Libby P. Molecular imaging of atherosclerosis for improving diagnostic and therapeutic development. Circ Res 2012;111:231–44.CrossRef
4.
go back to reference Townsend DW, Cherry SR. Combining anatomy and function: The path to true image fusion. Eur Radiol 2001;11:1968–74.CrossRef Townsend DW, Cherry SR. Combining anatomy and function: The path to true image fusion. Eur Radiol 2001;11:1968–74.CrossRef
5.
go back to reference Joshi NV, Vesey AT, Williams MC, Shah AS, Calvert PA, Craighead FH, et al. 18F-fluoride positron emission tomography for identification of ruptured and high-risk coronary atherosclerotic plaques: A prospective clinical trial. Lancet 2014;383:705–13.CrossRef Joshi NV, Vesey AT, Williams MC, Shah AS, Calvert PA, Craighead FH, et al. 18F-fluoride positron emission tomography for identification of ruptured and high-risk coronary atherosclerotic plaques: A prospective clinical trial. Lancet 2014;383:705–13.CrossRef
6.
go back to reference Surti S, Scheuermann J, Fakhri G, Daube-Witherspoon ME, Lim R, Abi-Hatem N, et al. Impact of time-of-flight PET on whole-body oncologic studies: A human observer lesion detection and localization study. J Nucl Med 2011;52:712–9.CrossRef Surti S, Scheuermann J, Fakhri G, Daube-Witherspoon ME, Lim R, Abi-Hatem N, et al. Impact of time-of-flight PET on whole-body oncologic studies: A human observer lesion detection and localization study. J Nucl Med 2011;52:712–9.CrossRef
7.
go back to reference Budinger TF. Time-of-flight positron emission tomography: Status relative to conventional PET. J Nucl Med 1983;24:73–8.PubMed Budinger TF. Time-of-flight positron emission tomography: Status relative to conventional PET. J Nucl Med 1983;24:73–8.PubMed
8.
go back to reference Karp JS, Surti S, Daube-Witherspoon ME, Muehllehner G. Benefit of time-of-flight in PET: Experimental and clinical results. J Nucl Med 2008;49:462–70.CrossRef Karp JS, Surti S, Daube-Witherspoon ME, Muehllehner G. Benefit of time-of-flight in PET: Experimental and clinical results. J Nucl Med 2008;49:462–70.CrossRef
9.
go back to reference Kobayashi Y, Kumita S, Fukushima Y, Ishihara K, Suda M, Sakurai M. Significant suppression of myocardial 18F-fluorodeoxyglucose uptake using 24-h carbohydrate restriction and a low-carbohydrate, high-fat diet. J Cardiol 2012;62:314–9.CrossRef Kobayashi Y, Kumita S, Fukushima Y, Ishihara K, Suda M, Sakurai M. Significant suppression of myocardial 18F-fluorodeoxyglucose uptake using 24-h carbohydrate restriction and a low-carbohydrate, high-fat diet. J Cardiol 2012;62:314–9.CrossRef
10.
go back to reference Fayad ZA, Mani V, Woodward M, Kallend D, Abt M, Burgess T, et al. Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-plaque): A randomised clinical trial. Lancet 2011;378:1547–59.CrossRef Fayad ZA, Mani V, Woodward M, Kallend D, Abt M, Burgess T, et al. Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-plaque): A randomised clinical trial. Lancet 2011;378:1547–59.CrossRef
11.
go back to reference Dunphy MP, Freiman A, Larson SM, Strauss HW. Association of vascular 18F-FDG uptake with vascular calcification. J Nucl Med 2005;46:1278–84.PubMed Dunphy MP, Freiman A, Larson SM, Strauss HW. Association of vascular 18F-FDG uptake with vascular calcification. J Nucl Med 2005;46:1278–84.PubMed
12.
go back to reference Rogers IS, Nasir K, Figueroa AL, Cury RC, Hoffmann U, Vermylen DA, et al. Feasibility of FDG imaging of the coronary arteries: Comparison between acute coronary syndrome and stable angina. JACC Cardiovasc Imaging 2010;3:388–97.CrossRef Rogers IS, Nasir K, Figueroa AL, Cury RC, Hoffmann U, Vermylen DA, et al. Feasibility of FDG imaging of the coronary arteries: Comparison between acute coronary syndrome and stable angina. JACC Cardiovasc Imaging 2010;3:388–97.CrossRef
13.
go back to reference Suzuki Y, Slmoka P, Wolak A, Ohba M, Suzuki S, Yang LD, et al. Motion-frozen myocardial perfusion SPECT improves detection of coronary artery disease in obese patients. J Nucl Med 2008;49:1075–9.CrossRef Suzuki Y, Slmoka P, Wolak A, Ohba M, Suzuki S, Yang LD, et al. Motion-frozen myocardial perfusion SPECT improves detection of coronary artery disease in obese patients. J Nucl Med 2008;49:1075–9.CrossRef
14.
go back to reference Srinivas S, Dhurairaj T, Basu S, Bural G, Surti S, Alavi A. A recovery coefficient method for partial volume correction of PET images. Ann Nucl Med 2009;23:341–8.CrossRef Srinivas S, Dhurairaj T, Basu S, Bural G, Surti S, Alavi A. A recovery coefficient method for partial volume correction of PET images. Ann Nucl Med 2009;23:341–8.CrossRef
15.
go back to reference Tahara N, Kai H, Yamagishi S, Mizoguchi M, Nakaura H, Ishibashi M, et al. Vascular inflammation evaluated by [18F]-fluorodeoxyglucose positron emission tomography is associated with the metabolic syndrome. J Am Coll Cardiol 2007;49:1533–9.CrossRef Tahara N, Kai H, Yamagishi S, Mizoguchi M, Nakaura H, Ishibashi M, et al. Vascular inflammation evaluated by [18F]-fluorodeoxyglucose positron emission tomography is associated with the metabolic syndrome. J Am Coll Cardiol 2007;49:1533–9.CrossRef
16.
go back to reference Myers KS, Rudd JH, Hailman EP, Bolognese JA, Burke J, Pinto CA, et al. Correlation between arterial FDG uptake and biomarkers in peripheral artery disease. JACC Cardiovasc Imaging 2012;5:38–45.CrossRef Myers KS, Rudd JH, Hailman EP, Bolognese JA, Burke J, Pinto CA, et al. Correlation between arterial FDG uptake and biomarkers in peripheral artery disease. JACC Cardiovasc Imaging 2012;5:38–45.CrossRef
17.
go back to reference Rudd JH, Myers KS, Bansilal S, Machac J, Woodward M, Fuster V, et al. Relationships among regional arterial inflammation, calcification, risk factors, and biomarkers: A prospective fluorodeoxyglucose positron-emission tomography/computed tomography imaging study. Circ Cardiovasc Imaging 2009;2:107–15.CrossRef Rudd JH, Myers KS, Bansilal S, Machac J, Woodward M, Fuster V, et al. Relationships among regional arterial inflammation, calcification, risk factors, and biomarkers: A prospective fluorodeoxyglucose positron-emission tomography/computed tomography imaging study. Circ Cardiovasc Imaging 2009;2:107–15.CrossRef
18.
go back to reference Wu YW, Kao HL, Chen MF, Lee BC, Tseng WY, Jeng JS, et al. Characterization of plaques using 18F-FDG PET/CT in patients with carotid atherosclerosis and correlation with matrix metalloproteinase-1. J Nucl Med 2007;48:227–33.PubMed Wu YW, Kao HL, Chen MF, Lee BC, Tseng WY, Jeng JS, et al. Characterization of plaques using 18F-FDG PET/CT in patients with carotid atherosclerosis and correlation with matrix metalloproteinase-1. J Nucl Med 2007;48:227–33.PubMed
19.
go back to reference Noh TS, Moon SH, Cho YS, Hong SP, Lee EJ, Choi JY, et al. Relation of carotid artery 18F-FDG uptake to C-reactive protein and Framingham risk score in a large cohort of asymptomatic adults. J Nucl Med 2013;54:2070–6.CrossRef Noh TS, Moon SH, Cho YS, Hong SP, Lee EJ, Choi JY, et al. Relation of carotid artery 18F-FDG uptake to C-reactive protein and Framingham risk score in a large cohort of asymptomatic adults. J Nucl Med 2013;54:2070–6.CrossRef
20.
go back to reference Tahara N, Kai H, Ishibashi M, Nakaura H, Kaida H, Baba K, et al. Simvastatin attenuates plaque inflammation: Evaluation by fluorodeoxyglucose positron emission tomography. J Am Coll Cardiol 2006;48:1825–31.CrossRef Tahara N, Kai H, Ishibashi M, Nakaura H, Kaida H, Baba K, et al. Simvastatin attenuates plaque inflammation: Evaluation by fluorodeoxyglucose positron emission tomography. J Am Coll Cardiol 2006;48:1825–31.CrossRef
21.
go back to reference Mizoguchi M, Tahara N, Tahara A, Nitta Y, Kodama N, Oba T, et al. Pioglitazone attenuates atherosclerotic plaque inflammation in patients with impaired glucose tolerance or diabetes a prospective, randomized, comparator-controlled study using serial FDG PET/CT imaging study of carotid artery and ascending aorta. JACC Cardiovasc Imaging 2011;4:1110–8.CrossRef Mizoguchi M, Tahara N, Tahara A, Nitta Y, Kodama N, Oba T, et al. Pioglitazone attenuates atherosclerotic plaque inflammation in patients with impaired glucose tolerance or diabetes a prospective, randomized, comparator-controlled study using serial FDG PET/CT imaging study of carotid artery and ascending aorta. JACC Cardiovasc Imaging 2011;4:1110–8.CrossRef
22.
go back to reference Vancraeynest D, Pasquet A, Roelants V, Gerber BL, Vanoverschelde JL. Imaging the vulnerable plaque. J Am Coll Cardiol 2011;57:1961–79.CrossRef Vancraeynest D, Pasquet A, Roelants V, Gerber BL, Vanoverschelde JL. Imaging the vulnerable plaque. J Am Coll Cardiol 2011;57:1961–79.CrossRef
Metadata
Title
The high matrix acquisition technique for imaging of atherosclerotic plaque inflammation in fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography with time-of-flight: Phantom study
Authors
Masaya Suda, PhD
Tomonari Kiriyama, MD
Keiichi Ishihara, MD
Masahisa Onoguchi, PhD
Yasuhiro Kobayashi, MD
Minoru Sakurai, BS
Takayuki Shibutani, MHSc
Shin-ichiro Kumita, MD
Publication date
01-08-2017
Publisher
Springer International Publishing
Published in
Journal of Nuclear Cardiology / Issue 4/2017
Print ISSN: 1071-3581
Electronic ISSN: 1532-6551
DOI
https://doi.org/10.1007/s12350-016-0510-7

Other articles of this Issue 4/2017

Journal of Nuclear Cardiology 4/2017 Go to the issue